DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Response to alendronate in osteoporotic women previously treated with pamidronate.

Author(s): Peretz A, Siderova V, Body JJ, Dumon JC, Rozenberg S, Fellemans C, Fuss M, Bergmann P, Interdisciplinary Group for the Study of Bone Diseases and Calcium metabolism (GIPOB)

Affiliation(s): The Internal Medicine Department, CHU Brugmann, 4 place Van Gehuchten, B-1020, Brussels, Belgium. anne.peretz@chu-brugmann.be

Publication date & source: 2003-02-25, Maturitas., 44(2):111-5.

Publication type: Clinical Trial; Randomized Controlled Trial

INTRODUCTION: Different bisphosphonates have been shown to increase bone mineral density (BMD) and reduce the risk of fracture in osteoporotic patients. It is unclear how shifting from a treatment with one bisphosphonate to another will influence the evolution of BMD and bone turnover. METHODS: In the present study, we followed BMD (DXA, Hologic QDR1000) of the lumbar spine (BMDL) and of the total hip (BMDH), bone alkaline phosphatase (Ostase, Hibritech), and urinary collagen cross links (pyridinoline, deoxypyridinoline, Biorad) in 39 patients treated with IV pamidronate (60 mg/3 months) since at least 2 years and who were shifted to oral alendronate (10 mg/day, n=18) or left to IV pamidronate (n=21) for 2 more years. RESULTS: BMD increased similarly and significantly in both groups after 2 additional years of treatment as compared to baseline (P<0.05, sign test). BMDL: +3.8% in the alendronate group vs +4.1% in the pamidronate group; BMDH: +4.3% in alendronate group vs +3.6% in pamidronate group, There was no significant change in the biological parameters of bone turnover in any group. CONCLUSION: The increase of BMD with both bisphosphonates in these previously treated patients was as expected after a 2 more years of treatment. Alendronate administration did not induce a larger gain in BMD as compared to cyclic pamidronate. Bone turnover was no longer affected by switching the bisphosphonate treatment.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017